Pipeline
Lead Asset: AGX-010
Targeted ADC - indications: TNBC, mUC, HR+/HER2- mBC
Preclinical
Preclinical
Target Indications
Triple-negative breast cancer (TNBC)
Muscle invasive urothelial carcinoma (mUC)
HR+/HER2- metastatic breast cancer (mBC)
Differentiation vs Trodelvy
AGX-010 demonstrates superior activity in preclinical TNBC tumor xenograft models—including TROP-2 low tumors where Trodelvy is inactive.
Safety Profile
The lack of expression in critical normal human tissues combined with the low expression in a limited number of normal human tissues suggest AGX-010 will have an excellent safety profile.
Key Advantages
- Novel tumor antigen targeting
- Superior preclinical efficacy
- Low normal tissue expression
- Multiple cancer indications
AGX-020
Undisclosed MMAE ADC program Early discovery solid tumors (target under evaluation)
Discovery
Discovery
AGX-030
Open to strategic business development opportunities
Discovery
Discovery